BC
Bain Capital Life Sciences Investors, LLC
13F filer · CIK 0001703031Reported Aug 14, 2026
Net buyer this quarter
13F portfolio value$1.68BU.S. long equity reported on 13F
Positions212 new · 1 closed
Net flow last quarter+$434MBuys minus sells
Top 10 positions weight87.9%Concentration
Holdings
13F · last 4 quarters freeScroll for earlier quarters
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q2 2026Reported Aug 14, 202621 positions | |||||
| $498M | 29.58% | 17.42% | New | Q2 2026 | |
| $248M | 14.74% | 9.74% | -19.1% | Q3 2025 | |
| $129M | 7.67% | 3.24% | -47.9% | Q4 2022 | |
| $108M | 6.45% | 8.57% | Not reported | Q4 2019 | |
| $102M | 6.04% | 1.16% | +217.7% | Q1 2026 | |
| $98M | 5.83% | 9.33% | Not reported | Q1 2018 | |
| $92.5M | 5.50% | 4.10% | Not reported | Q1 2021 | |
| $88.6M | 5.27% | 8.10% | -5.2% | Q4 2024 | |
| $60.6M | 3.60% | 3.53% | New | Q2 2026 | |
| $53.6M | 3.19% | 10.57% | +78.2% | Q2 2023 | |
| $37.2M | 2.21% | 8.29% | Not reported | Q4 2019 | |
| $35.3M | 2.10% | 0.66% | Not reported | Q1 2024 | |
| $33.5M | 1.99% | 5.84% | Not reported | Q4 2020 | |
| $25.7M | 1.53% | 4.69% | -7.2% | Q1 2024 | |
| $25.3M | 1.51% | 2.97% | -14.9% | Q3 2020 | |
| $14.6M | 0.87% | Not reported | Not reported | Q3 2021 | |
| $10.3M | 0.61% | 0.37% | Not reported | Q1 2023 | |
| $9.65M | 0.57% | 2.59% | -12.1% | Q4 2020 | |
| $6.36M | 0.38% | 10.09% | Not reported | Q4 2021 | |
| $4.16M | 0.25% | 1.10% | -30.7% | Q4 2024 | |
| $2.14M | 0.13% | Not reported | Not reported | Q4 2022 | |
| Q1 2026Reported May 15, 202620 positions | |||||
| $254M | 22.93% | 12.13% | -16.1% | Q3 2025 | |
| $234M | 21.09% | 6.26% | Not reported | Q4 2022 | |
| $111M | 10.05% | 8.56% | -12.2% | Q4 2024 | |
| $96.1M | 8.67% | 8.59% | Not reported | Q4 2019 | |
| $75.6M | 6.82% | 4.10% | -4.5% | Q1 2021 | |
| $70.6M | 6.37% | 9.97% | +24.0% | Q1 2018 | |
| $32.9M | 2.97% | 8.45% | Not reported | Q4 2019 | |
| $30.4M | 2.74% | 0.66% | -51.3% | Q1 2024 | |
| $28.9M | 2.60% | 3.49% | -0.7% | Q3 2020 | |
| $26.8M | 2.42% | 5.14% | Not reported | Q1 2024 | |
| $26M | 2.35% | 8.69% | Not reported | Q2 2023 | |
| CPCNTACentessa Pharmaceuticals PLC | $25.2M | 2.27% | 0.41% | New | Q1 2026 |
| $21.6M | 1.95% | 0.37% | New | Q1 2026 | |
| $19.1M | 1.73% | Not reported | Not reported | Q3 2021 | |
| $18.9M | 1.70% | 6.89% | Not reported | Q4 2020 | |
| $12.7M | 1.15% | 2.95% | -5.0% | Q4 2020 | |
| $9.03M | 0.81% | 0.37% | Not reported | Q1 2023 | |
| $7.8M | 0.70% | 1.59% | -34.8% | Q4 2024 | |
| $5.58M | 0.50% | 11.48% | +26.1% | Q4 2021 | |
| $2M | 0.18% | Not reported | Not reported | Q4 2022 | |
| Q4 2025Reported Feb 17, 202619 positions | |||||
| $363M | 27.79% | 14.60% | Not reported | Q3 2025 | |
| $256M | 19.63% | 6.39% | -31.8% | Q4 2022 | |
| $213M | 16.29% | 10.46% | +24.3% | Q4 2024 | |
| $106M | 8.13% | 8.60% | Not reported | Q4 2019 | |
| $77.8M | 5.96% | 4.30% | -11.9% | Q1 2021 | |
| $44.6M | 3.42% | 10.02% | Not reported | Q1 2018 | |
| $36.1M | 2.76% | 2.45% | -45.5% | Q4 2024 | |
| $31.9M | 2.44% | 8.76% | +227.0% | Q4 2019 | |
| $30.6M | 2.35% | 1.72% | -43.5% | Q1 2024 | |
| $29.2M | 2.24% | 5.15% | -7.7% | Q1 2024 | |
| $26.4M | 2.02% | 3.51% | Not reported | Q3 2020 | |
| $24.5M | 1.87% | Not reported | Not reported | Q3 2021 | |
| $21.2M | 1.62% | 9.63% | Not reported | Q2 2023 | |
| $13.7M | 1.05% | 7.40% | +545.0% | Q4 2020 | |
| MTMRSNMersana Therapeutics, Inc. | $10M | 0.77% | 6.93% | Not reported | Q2 2020 |
| $8.87M | 0.68% | 3.18% | Not reported | Q4 2020 | |
| $5.79M | 0.44% | 0.48% | -75.9% | Q3 2021 | |
| $4.72M | 0.36% | 162.73% | +61.4% | Q4 2021 | |
| $2.3M | 0.18% | Not reported | 0.0% | Q4 2022 | |
| Q3 2025Reported Nov 14, 202521 positions | |||||
| $419M | 27.81% | 14.91% | New | Q3 2025 | |
| $305M | 20.23% | 9.47% | Not reported | Q4 2022 | |
| CTCDTXCidara Therapeutics, Inc. | $289M | 19.20% | 10.30% | +20.8% | Q3 2024 |
| $79.4M | 5.27% | 5.85% | -3.7% | Q1 2021 | |
| $67M | 4.45% | 9.97% | Not reported | Q4 2024 | |
| $62.8M | 4.17% | 10.18% | Not reported | Q4 2019 | |
| $51.8M | 3.44% | 3.07% | -47.0% | Q1 2024 | |
| $48.8M | 3.24% | 10.16% | Not reported | Q1 2018 | |
| $45.9M | 3.05% | 4.52% | Not reported | Q4 2024 | |
| $28.2M | 1.87% | Not reported | Not reported | Q3 2021 | |
| $22.8M | 1.51% | 2.43% | Not reported | Q3 2021 | |
| $22.6M | 1.50% | 10.05% | Not reported | Q2 2023 | |
| $20.2M | 1.34% | 7.69% | Not reported | Q1 2024 | |
| $16M | 1.06% | 4.80% | Not reported | Q3 2020 | |
| $8.33M | 0.55% | 9.69% | +332.1% | Q4 2019 | |
| $7.21M | 0.48% | 3.18% | Not reported | Q4 2020 | |
| $3.85M | 0.26% | 8.81% | Not reported | Q4 2021 | |
| MTMRSNMersana Therapeutics, Inc. | $2.69M | 0.18% | 6.93% | -96.0% | Q2 2020 |
| $2.47M | 0.16% | 1.50% | Not reported | Q4 2020 | |
| $1.76M | 0.12% | 4.09% | -34.6% | Q2 2024 | |
| $1.71M | 0.11% | Not reported | Not reported | Q4 2022 | |
Premium opens every quarter this fund has filed